Determining the clinical relevance of the inTeraction between AprepitaNt aNd EtoposiDe; an observational pharmacokinetic study (TANNED-study)

Determining the clinical relevance of the inTeraction between AprepitaNt aNd EtoposiDe; an observational pharmacokinetic study (TANNED-study) - TANNED

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50969

Enrollment

Registered

2021-03-22

Start date

2021-08-11

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

testicular cancer testicular germ cell tumor

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: • Patients with TC who will start or already started treatment with (B)EP • Age of at least 18 years • Patients from whom it is possible to collect blood samples • Patients who are able and willing to give written informed consent prior to screening

Exclusion criteria

Exclusion criteria: • Patients who are co-treated with drugs that could interfere with the metabolism of etoposide (including drugs classified as a weak, moderate or strong CYP3A4 inhibitor OR weak, moderate and strong inducers of CYP3A4 according to the table based on the Flockhart table).

Design outcomes

Primary

Measure	Time frame
the exposure (AUC0-24 hr) to etoposide in TC patients treated with (B)EP.	—

Countries

Netherlands

Outcome results